statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, Aligos ), a clinical stage biopharmaceutical company focused on developing novel...

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, Aligos ), a clinical stage biopharmaceutical company focused on developing novel...

Aligos Therapeutics initiates Phase 2a HERALD study of ALG-055009

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Screening of subjects has begun at clinical study sitesThe Phase 2a study is being led by Principal Investigator, Dr. Stephen HarrisonAligos anticipates dosing the first subject in Q2 2024 with...

Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Grows By 16.4%

Aligos Therapeutics, Inc. (NASDAQ:ALGS  Get Free Report) saw a large increase in short interest during the month of February. As of February 29th, there was short interest totalling 369,100...

Recap: Aligos Therapeutics Q4 Earnings

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, Aligos ), a clinical stage biopharmaceutical company focused on developing novel...

Piper Sandler Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Aligos Therapeutics (ALGS Research Report) today and set a price target of $7.00...

Aligos Therapeutics to host conference call

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

Volume	55,068.00
52-Wk High	$1.20
52-Wk Low	$0.3482

Current Price	$0.5399
Prev Close	$0.54
Open	$0.5398
Dividend Yield	0.00%
50-Day Moving Average	$0.5223
Beta	1.04
Avg. Volume	479,808.42
PE Ratio	N/A

52-Week High	$1.20
52-Week Low	$0.3482
Market Capitalization	$42.17M
EPS	N/A
Price to Book	0.68
Revenue Per Employee	$208,969.70
Enterprise Value/EBITDA	-0.61

ALGS Aligos Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals